European Journal of Cancer
Volume 44, Issue 1 , Pages 19-24 , January 2008

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

  • Christopher M. Booth

      Affiliations

    • National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, ON, Canada K7L 3N6
    • Research Fellow, NCIC Clinical Trials Group.
  • ,
  • A. Hilary Calvert

      Affiliations

    • Northern Institute for Cancer Research, Medical School, Newcastle upon Tyne, UK
  • ,
  • Giuseppe Giaccone

      Affiliations

    • Medical Oncology Branch, National Cancer Institute, Bethesda, USA
  • ,
  • Marinus W. Lobbezoo

      Affiliations

    • NDDO Research Foundation, Amsterdam, The Netherlands
  • ,
  • Lesley K. Seymour

      Affiliations

    • National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, ON, Canada K7L 3N6
  • ,
  • Elizabeth A. Eisenhauer

      Affiliations

    • National Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Kingston, ON, Canada K7L 3N6
    • Corresponding Author InformationCorresponding author: Tel.: +1 613 533 6430; fax: +1 613 533 2941.
  • ,
  • On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies

Received 26 July 2007 ,Accepted 31 July 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(07)00589-8

doi: 10.1016/j.ejca.2007.07.034

European Journal of Cancer
Volume 44, Issue 1 , Pages 19-24 , January 2008